Skip To Main Content
Michio Tokuyama on Muck Rack

Michio Tokuyama

As seen in: Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michio

Contact Michio, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Summary of certolizumab pegol in psoriasis including structural features, pharmacokinetics and treatment | Immunotherapy

|
By Tomotaka Mabuchi, Michio Tokuyama
| Future Medicine Verified
Psoriasis pathogenesis involves TNF-α, IL-23 and IL17, against which biologics have been highly effective. Among the five TNF-α inhibitors available for psoriasis, namely infliximab, adalimumab, etanercept, golimumab and certolizumab pegol (CZP), CZP has a unique mechanism of action due to its structure. As CZP lacks the Fc region, it does not cross the placenta and can be safely used in pregnant women.
Open in Who Shared Issue with article?
See all 1 articles